Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for Hidradenitis Suppurativa (HiGUS)
NCT04061395Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guselkumab in hidradenitis suppurativa (HS), sponsored by University Medical Center Groningen. Primary endpoint: Changes in inflammatory pathways induced by IL-23p19 blockade at Week 16. Started Oct 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04061395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061395.